Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ -- Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,...

Read More